Uptravi and Olmetec drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Uptravi (selexipag) and Olmetec (olmesartan medoxomil). Common drug interactions include headache among females and headache among males.

The phase IV clinical study analyzes what interactions people have when they take Uptravi and Olmetec. It is created by eHealthMe based on reports of 25 people who take the same drugs from the FDA, and is updated regularly.

What is Uptravi?

Uptravi has active ingredients of selexipag. eHealthMe is studying from 26,576 Uptravi users. Check the latest studies of Uptravi.

What is Olmetec?

Olmetec has active ingredients of olmesartan medoxomil. It is often used in high blood pressure. eHealthMe is studying from 7,904 Olmetec users. Check the latest studies of Olmetec.

On Jul, 23, 2026

25 people who take Uptravi and Olmetec together, and have interactions are studied.

What are the common drug interactions of Uptravi and Olmetec, by gender? *:

female:

Headache (pain in head)
Pulmonary arterial hypertension (high blood pressure in the arteries of lungs)
Pleural effusion (water on the lungs)
Aortic aneurysm (enlargement of an aortic artery caused by a weakening of the artery wall)
Ascites (accumulation of fluid in the abdominal cavity)
Brain herniation (brain herniation is a potentially deadly side effect of very high intracranial pressure that occurs when a part of the brain is squeezed across structures within the skull)
Brain natriuretic peptide increased
Chronic gastritis (long lasting infection of stomach lining)
Craniotomy
Depression

male:

Headache (pain in head)
Cardiac failure
Renal impairment (severely reduced kidney function)
Drug eruption (adverse drug reaction of the skin)
Dyspnoea (difficult or laboured respiration)
Interstitial lung disease
Pain in jaw
Palpitations (feelings or sensations that your heart is pounding or racing)
Tinnitus (a ringing in the ears)
Diarrhoea

What are the common drug interactions of Uptravi and Olmetec, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Blood creatinine increased
Brain natriuretic peptide increased
Cardiac failure
Diarrhoea
Hypotension (abnormally low blood pressure)
Renal failure (kidney dysfunction)
Headache (pain in head)
Blood pressure decreased
Renal impairment (severely reduced kidney function)

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

Headache (pain in head)
Pulmonary arterial hypertension (high blood pressure in the arteries of lungs)
Craniotomy
Depression
Diarrhoea
Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
Hepatic enzyme increased
Hypokalaemia (low potassium)
Hypotension (abnormally low blood pressure)
Hypoxia (low oxygen in tissues)

What are the existing conditions these people have? *

Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 25 people, 100.00%
Cardiac Failure: 12 people, 48.00%
Right Ventricular Failure (right half of the heart fails to work): 9 people, 36.00%
Hypokalemia (low potassium): 9 people, 36.00%
Ascites (accumulation of fluid in the abdominal cavity): 7 people, 28.00%
Fever: 7 people, 28.00%
Pleural Effusion (water on the lungs): 7 people, 28.00%
Systemic Sclerosis (Scleroderma) (an autoimmune or connective tissue disease. it is characterized by thickening of the skin): 7 people, 28.00%
Diarrhea: 7 people, 28.00%
Subdural Haematoma (blood collects between the skull and the surface of the brain): 6 people, 24.00%

* Approximation only. Some reports may have incomplete information.

Do you take Uptravi and Olmetec?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously